The “FSD Pharma issues corporate updates” public release (April 7, 2022)
The “FSD Pharma closes cad$16.4 million sale of non-core assets” public release
New MorningStar report issued highlighting FSD Pharma (NASDAQ: HUGE) (TSX: HUGE)
   
FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
FSD Pharma announced the submission of an Investigational New Drug or “IND” application
International Business Times publishes article featuring FSD Pharma: "Multiple Sclerosis to Depression, Innovative Biotech aims for Total Brain Health"
   
The Benzinga article – “Multiple Sclerosis Affects Millions Of People - Mostly Women, And There Is No Cure. What Is Being Done?”
The “FSD Pharma closes cad$16.4 million sale of non-core assets” public release
The “FSD Pharma Files Investigational New Drug Application (“IND”) with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory disorder and Provides Corporate Updates” public release

Receive most valuable updates straight into your inbox

SIGN UP TODAY



PLEASE SEND INVESTOR INQUIRIES TO [email protected]

ALL OTHER INQUIRIES PLEASE EMAIL [email protected]

JOIN OUR TEAM

Careers

    Email Alerts

    Please fill out the form below to receive company press releases via email when they occur.


    Contact




      PLEASE SEND INVESTOR INQUIRIES TO [email protected]


      ALL OTHER INQUIRIES PLEASE EMAIL TO [email protected]




      TOP